La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Sihuan Pharmaceutical Holdings Group Gestion

Gestion contrôle des critères 3/4

Le PDG Sihuan Pharmaceutical Holdings Group's est Weicheng Guo, nommé en Oct2014, a un mandat de 9.83 ans. La rémunération annuelle totale est CN¥ 3.00M, composée du salaire de 100% et des bonus 0%, y compris les actions et options de la société. détient directement 0.12% des actions de la société, d'une valeur de HK$ 6.02M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.8 ans et 8.4 ans.

Informations clés

Weicheng Guo

Directeur général

CN¥3.0m

Rémunération totale

Pourcentage du salaire du PDG	100.0%
Durée du mandat du directeur général	9.9yrs
Propriété du PDG	0.1%
Durée moyenne d'occupation des postes de direction	1.9yrs
Durée moyenne du mandat des membres du conseil d'administration	8.5yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Weicheng Guo a-t-elle évolué par rapport aux bénéfices de Sihuan Pharmaceutical Holdings Group?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-CN¥38m
Mar 31 2024	n/a	n/a	-CN¥46m
Dec 31 2023	CN¥3m	CN¥3m	-CN¥54m
Jun 30 2023	n/a	n/a	-CN¥2b
Mar 31 2023	n/a	n/a	-CN¥2b
Dec 31 2022	CN¥3m	CN¥3m	-CN¥2b
Jun 30 2022	n/a	n/a	-CN¥144m
Mar 31 2022	n/a	n/a	CN¥141m
Dec 31 2021	CN¥6m	CN¥6m	CN¥427m
Sep 30 2021	n/a	n/a	CN¥681m
Jun 30 2021	n/a	n/a	CN¥945m
Mar 31 2021	n/a	n/a	CN¥727m
Dec 31 2020	CN¥6m	CN¥6m	CN¥508m
Sep 30 2020	n/a	n/a	-CN¥14m
Jun 30 2020	n/a	n/a	-CN¥537m
Mar 31 2020	n/a	n/a	-CN¥2b
Dec 31 2019	CN¥6m	CN¥6m	-CN¥3b
Sep 30 2019	n/a	n/a	-CN¥2b
Jun 30 2019	n/a	n/a	-CN¥1b
Mar 31 2019	n/a	n/a	CN¥238m
Dec 31 2018	CN¥6m	CN¥6m	CN¥2b
Sep 30 2018	n/a	n/a	CN¥1b
Jun 30 2018	n/a	n/a	CN¥1b
Mar 31 2018	n/a	n/a	CN¥1b
Dec 31 2017	CN¥6m	CN¥6m	CN¥1b

Rémunération vs marché: La rémunération totale de Weicheng ($USD 419.92K ) est dans la moyenne des entreprises de taille similaire sur le marché Hong Kong ($USD 469.55K ).

Rémunération et revenus: La rémunération de Weicheng a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Weicheng Guo (60 yo)

9.9yrs

Titularisation

CN¥3,000,000

Compensation

Dr. Weicheng Guo co-founded Sihuan Pharmaceutical Holdings Group Ltd. and has been its Chief Executive Officer since October 20, 2014. Dr. Guo is responsible for the overall operations of Sihuan Pharmaceut...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Fengsheng Che	Co-Founder & Executive Chairman	18.3yrs	CN¥7.00m	5.37% CN¥ 290.0m
Weicheng Guo	Deputy Chairman & CEO	9.9yrs	CN¥3.00m	0.12% CN¥ 6.6m
Guili Miao	Deputy CEO	1.9yrs	CN¥5.05m	pas de données
Jionglong Zhang	Executive Director	3.8yrs	CN¥646.00k	2.15% CN¥ 116.0m
Yanling Chen	Joint Company Secretary & Executive Director	1.9yrs	CN¥1.77m	pas de données
Kin Wai Li	Joint Company Secretary	1.9yrs	pas de données	pas de données
Xianhui Meng	Deputy General Manager	no data	CN¥4.26m	pas de données

1.9yrs

Durée moyenne de l'emploi

60yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 460 n'est pas considérée comme expérimentée (ancienneté moyenne 1.8 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Fengsheng Che	Co-Founder & Executive Chairman	18.3yrs	CN¥7.00m	5.37% CN¥ 290.0m
Weicheng Guo	Deputy Chairman & CEO	18.3yrs	CN¥3.00m	0.12% CN¥ 6.6m
Guili Miao	Deputy CEO	1.9yrs	CN¥5.05m	pas de données
Jionglong Zhang	Executive Director	6.4yrs	CN¥646.00k	2.15% CN¥ 116.0m
Yanling Chen	Joint Company Secretary & Executive Director	6.4yrs	CN¥1.77m	pas de données
Wah Kwong Tsang	Independent Non-Executive Director	11yrs	CN¥371.00k	pas de données
Xun Zhu	Independent Non-Executive Director	10.6yrs	CN¥371.00k	pas de données
Guan Wang	Independent Non-Executive Director	1.4yrs	CN¥202.00k	pas de données

8.5yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 460 sont considérés comme expérimentés (ancienneté moyenne 8.4 ans).

Sihuan Pharmaceutical Holdings Group Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Less than half of directors are independent

Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes

Less than half of directors are independent

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022

Deputy General Manager recently bought HK$19m worth of stock

Recent updates

Upcoming dividend of HK$0.021 per share

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.005 loss in 1H 2023)

Sihuan Pharmaceutical Holdings Group Ltd. Announces Interim Ordinary Cash Dividend for the Six Months Ended June 30, 2024, Payable on 10 October 2024

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Sihuan Pharmaceutical Holdings Group Ltd.'s Honghe Pharmaceutical Co., Ltd. Obtains Drug Registration Approval from National Medical Products Administration

New major risk - Revenue and earnings growth

Sihuan Pharmaceutical Holdings Group Ltd. Announces Rivaroxaban Tablets (Strength: 2.5Mg) Obtained Drug Registration Approval from NMPA

Now 21% undervalued after recent price drop

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets

Now 20% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes

National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical

First half 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.004 profit in 1H 2022)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Sihuan Pharmaceutical Holdings Group Ltd. Announces Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval for Clinical Trial

Sihuan Pharmaceutical Holdings Group Ltd. Announces Approval of Phase II Clinical Trial Application of Birociclib by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration

Upcoming dividend of HK$0.037 per share at 9.7% yield

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.044 profit in FY 2021)

Sihuan Pharmaceutical Holdings Group Ltd. Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Less than half of directors are independent

Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes

Upcoming dividend of HK$0.037 per share

Sihuan Pharmaceutical Holdings Group Ltd. Declares Special Cash Dividend for the Six Months Ended 30 June 2022, Payable on or Around 13 October 2022

First half 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.065 in 1H 2021)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2022 Results on Aug 30, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Acceptance of Application for Marketing of Xuanzhu Biopharm\U0027s Drug Fulvestrant Injection by Nmpa of China

Upcoming dividend of HK$0.13 per share

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Sihuan Pharmaceutical Obtains Class III Medical Device Registration Certificate from NMPA for Exclusively Distributed Hyaluronic Acid Persnica

Now 20% undervalued

Full year 2021 earnings released: EPS: CN¥0.044 (vs CN¥0.054 in FY 2020)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2021, Payable on June 14, 2022

Investor sentiment deteriorated over the past week

Now 25% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces First Class I Macromolecule Innovative Drug Her2 Bispecific Antibody Xzp-Km257 Was Approves for Clinical Trails

Investor sentiment improved over the past week

National Medical Products Administration Accepts Biologics License Application of Insulin Aspart Injection, Insulin Aspart 30 Injection and Insulin Aspart 50 Injection of Jilin Huisheng Biopharmaceutical Co., Ltd

Now 22% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces Medical Device Registration Certificate Obtained for Medical Skin Care Gel and Repair Gel

Sihuan Pharmaceutical Holdings Group Ltd. Announces Fondaparinux Sodium Injection Obtained Manufacture Approval

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS CN¥0.065 (vs CN¥0.018 in 1H 2020)

Non-Executive Director Jin-ha Kim has left the company

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.016 per share

Sihuan Pharmaceutical Holdings Group Ltd. Announces Obtains Drug Registration Approval in Relation to Caspofungin Acetate for Injection

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Final Cash Dividend for the Year Ended December 31, 2020, Payable on or Around July 15, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Two Special Cash Dividends

Full year 2020 earnings released: EPS CN¥0.054 (vs CN¥0.29 loss in FY 2019)

Sihuan Pharmaceutical Holdings Group Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: HK$2.68

Sihuan Pharmaceutical Holdings Group Ltd. Announces Selection of its Pantoprazole Sodium Injection (Panzuoer® 40mg per unit) and Ibuprofen Injection (Falanfen® 4ml: 0.4g, Tenaan® 8ml: 0.8g) in the Fourth Batch of National Drug Centralized Procurement

Sihuan Pharmaceutical Holdings Group Ltd. Announces Cinepazide Maleate Injection Obtain Approval from the National Medical Products Administration

New 90-day high: HK$1.32

Upcoming Dividend of HK$0.035 Per Share

Sihuan Pharmaceutical Holdings Group Ltd.(SEHK:460) dropped from FTSE All-World Index (USD)

First half earnings released

Deputy General Manager recently bought HK$19m worth of stock

Earnings released

New 90-day high - HK$1.03